A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

A Phase I Study of Ridaforolimus (MK8669) and MK0646 in Patients With Advanced Cancer

This study is being done to find the best tolerated dose of ridaforolimus and dalotuzumab in patients who have advanced cancer and to observe any anti-tumor activity in these patients.

Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009

Inclusion Criteria:

• You must have confirmed metastatic or advanced cancer that has not responded to standard therapy or where standard therapy does not exist
• In Part C, patients must have a diagnosis of advanced or metastatic colorectal adenocarcinoma or non-small cell lung cancer, and must have received at least 1 but no more than three prior systemic therapy treatment regimens
• You must be over the age of 18 years old
• You must have a ECOG status performance of 0 or 1
• You must have good organ function
• You must be willing to have skin and/or tumor biopsies

Exclusion Criteria:

• You have had cancer treatment within 4 weeks prior to entering the study or you still have bad side effects from previous therapies
• You have an active infection that requires treatment
• You are HIV positive or have a history of Hepatitis B or C